Hyperfine, Inc. Announces Promotions of Two Key Clinical Affairs Executives
New vice presidents of medical affairs and scientific affairs will support brain health innovation
GUILFORD, Conn. – October 10, 2023 – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced the promotions of neuroradiologists, Dr. Edmond Knopp and Dr. Chip Truwit. Effective immediately, Drs. Knopp and Truwit will be taking on new roles as vice president of medical affairs and vice president of scientific affairs, respectively.
As vice president of medical affairs, Dr. Knopp will interface with medical professionals, guide clinical studies, and champion the commitment of Hyperfine, Inc. to further ultra-low-field brain imaging to advance brain health, particularly in the areas of stroke care and disease-modifying therapies for Alzheimer’s.
Dr. Knopp joined Hyperfine, Inc. in 2021 and brings three decades of experience in radiology, neuroradiology, and MR imaging. A faculty member and leader at the New York University School of Medicine Department of Radiology, Dr. Knopp holds positions as a Senior American Society of Neuroradiology member and was an American Board of Radiology examiner. He was honored with the 2015 American Board of Radiology Lifetime Service Award, has been an advisor to the acclaimed International Diagnostic Course in Radiology (Neuroradiology) Davos, and was inducted as a fellow in the American Society of Functional Neuroradiology. Dr. Knopp graduated with a Bachelor of Science in Biology from Emory University and attained his Doctor of Medicine from SUNY Downstate Medical Center.
In the role of vice president of scientific affairs, Dr. Chip Truwit will spearhead clinical innovation projects, supporting the Swoop® system’s continued advancement. With a background rich in pediatric neuroradiology and the healthcare industry, Dr. Truwit is well-positioned at Hyperfine, Inc. to focus on the company’s future technology developments supporting global brain health and expanded access to care.
Dr. Chip Truwit joined Hyperfine, Inc. in 2022 and has over three decades of experience in academic and clinical radiology. Dr. Truwit previously served as the chief innovation officer and chief of radiology at Hennepin Healthcare, chief medical officer - diagnostic imaging at Philips, and emeritus professor of radiology at the University of Minnesota. He co-founded Image-guided Neurologics, which exited to Medtronic in 2005. He holds 29 patents, has authored over 130 neuroscience articles and four books, and is an internationally recognized lecturer on the imaging of pediatric neuroimaging, head trauma, and stroke. Dr. Truwit completed his Bachelor of Science in International Politics and Doctor of Medicine at Georgetown University and his neuroradiology training at the University of California, San Francisco.
“These leadership appointments underscore our commitment to developing ultra-low-field MR brain imaging to advance brain health,” said Maria Sainz, president and CEO of Hyperfine, Inc. “We are incredibly proud and fortunate to entrust Drs. Knopp and Truwit to provide the medical and scientific expertise and guide our development, clinical, and commercial efforts with ultra-low-field brain imaging.”
For more information about the Swoop® Portable MR Imaging® System, please visit hyperfine.io.
About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.
The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.
Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
# # #
Gilmartin Group LLC